Form 4: Arcus Biosciences President Sells Shares to Cover Tax Obligations

Arcus Biosciences President, Juan C. Jaen, sold 17,286 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Juan C. Jaen, President of Arcus Biosciences, sold 17,286 shares of common stock on December 15, 2024.
• The sale was executed at a price of $16.08 per share.
• This transaction was a 'net settlement' by the company to cover tax withholding obligations related to the vesting of previously granted restricted stock units (RSUs).
• Following the transaction, Mr. Jaen directly owns 317,220 shares of common stock and indirectly owns 1,188,233 shares through a trust.

Sentiment

Score: 5

Explanation: The document reflects a neutral event, a routine stock sale for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, which is common in publicly traded companies. It does not indicate any change in the company's outlook or performance.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a standard practice across the biotechnology industry.
• Many companies use restricted stock units (RSUs) as part of their compensation packages, and net settlements are a common mechanism to handle the tax implications of vesting.
• Similar transactions are regularly reported by executives at comparable companies such as Gilead Sciences, Regeneron, and Vertex Pharmaceuticals.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not indicate any change in the company's performance or outlook.

Key Dates

Keywords

Arcus Biosciences, insider trading, stock sale, Form 4, Juan C. Jaen, restricted stock units, tax obligations, executive compensation